The biomedical bubble

[1]  P. Cullinan,et al.  Every breath we take: The lifelong impact of air pollution, Report of a working party. , 2016 .

[2]  James Wilsdon,et al.  See-Through Science : Why Public Engagement Needs to Move Upstream , 2004 .

[3]  D. Fanelli.  How Many Scientists Fabricate and Falsify Research? A Systematic Review and Meta-Analysis of Survey Data , 2009, PloS one.

[4]  V. Quirke.  Putting Theory into Practice: James Black, Receptor Theory and the Development of the Beta-Blockers at ICI, 1958–1978 , 2006, Medical History.

[5]  Simon Capewell,et al.  Explaining the Decline in Coronary Heart Disease Mortality in England and Wales Between 1981 and 2000 , 2004, Circulation.

[6]  C. Team.  What is equality, diversity and inclusion? , 2017 .

[7]  E. D. Ranieri.  Science benefits from diversity , 2018, Nature.

[8]  Paul Nightingale,et al.  The myth of the biotech revolution. , 2004, Trends in biotechnology.

[9]  Response to centre for data ethics and innovation consultation , 2018 .

[10]  Ulrike Felt,et al.  Unsustainable Growth, Hyper-Competition, and Worth in Life Science Research: Narrowing Evaluative Repertoires in Doctoral and Postdoctoral Scientists’ Work and Lives , 2016, Minerva.

[11]  P. Burridge,et al.  Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom , 2016, BMC Medicine.

[12]  William Bains,et al.  Wasting cash—the decline of the British biotech sector , 2009, Nature Biotechnology.

[13]  N. Edwards.  Bad Pharma , 2013 .

[14]  Eric M. Ramirez-Weaver,et al.  A saving science , 2017 .

[15]  A. Stirling.  “Opening Up” and “Closing Down” , 2008 .

[16]  J. Ioannidis,et al.  What Happens When Underperforming Big Ideas in Research Become Entrenched? , 2016, JAMA.

[17]  W. Bains,et al.  Funding biotech start-ups in a post-VC world , 2014 .

[18]  Alfredo Yegros,et al.  Is Research Responding to Health Needs? , 2017 .

[19]  J. Brooks.  Why most published research findings are false: Ioannidis JP, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece , 2008 .

[20]  Lisa Urquhart,et al.  Market watch: Top drugs and companies by sales in 2017 , 2018, Nature Reviews Drug Discovery.

[21]  P. Glasziou,et al.  Avoidable waste in the production and reporting of research evidence. , 2009, Obstetrics and gynecology.

[22]  Howard Davies.  A crisis of trust , 2009 .

[23]  D. Sornette,et al.  Innovation as a social bubble: The example of the Human Genome Project , 2011 .

[24]  R. Veugelers.  The embodiment of knowledge: universities as engines of growth , 2016 .

[25]  A. Stirling.  A general framework for analysing diversity in science, technology and society , 2007, Journal of The Royal Society Interface.

[26]  M. Hopkins,et al.  Science, the State and the City: Britain's Struggle to Succeed in Biotechnology , 2016 .

[27]  Varun Sivaram,et al.  Venture Capital and Cleantech: The Wrong Model for Energy Innovation , 2016 .

[28]  W. MacNee,et al.  Combustion-derived nanoparticles: A review of their toxicology following inhalation exposure , 2005, Particle and Fibre Toxicology.

[29]  David F. Horrobin,et al.  Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.

[30]  Jack W Scannell,et al.  When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis , 2016, PloS one.

[31]  K. W. Phillips,et al.  How diversity works. , 2014, Scientific American.

[32]  M. Murphy.  Amyloid-Beta Solubility in the Treatment of Alzheimer's Disease. , 2018, The New England journal of medicine.

[33]  Michael Marmot,et al.  Fair society, healthy lives : the Marmot Review : strategic review of health inequalities in England post-2010. , 2010 .

[34]  Bernard Rachet,et al.  40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study , 2015, The Lancet.

[35]  Eileen A. Hogan.  The Attention Economy: Understanding the New Currency of Business , 2001 .

[36]  David J. Nicholls,et al.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca , 2018, Nature Reviews Drug Discovery.

[37]  S. Goodman,et al.  Meta-research: Evaluation and Improvement of Research Methods and Practices , 2015, PLoS biology.

[38]  R. Harris,et al.  Rigor Mortis: How Sloppy Science Creates Worthless Cures, Crushes Hope, and Wastes Billions , 2017 .

[39]  E. Stokstad.  A research behemoth is born in Britain. , 2018, Science.

[40]  Davide Chiaroni,et al.  Forms of creation of industrial clusters in biotechnology , 2006 .

[41]  B. Menne,et al.  Climate change and infectious diseases in Europe , 2010 .

[42]  C. Pérez.  Technological revolutions and financial capital : the dynamics of bubbles and golden ages , 2003 .

[43]  Jack Stilgoe,et al.  Machine learning, social learning and the governance of self-driving cars , 2017, Social studies of science.

[44]  J W Scannell,et al.  Financial returns on R&D: looking back at history, looking forward to adaptive licensing. , 2015, Reviews on recent clinical trials.

[45]  Paula E. Stephan.  How Economics Shapes Science , 2012 .

[46]  T. Evans.  Best research for best health: a new national health research strategy. , 2006, Clinical medicine.

[47]  Hector Hernandez Guevara,et al.  The 2016 EU Industrial R&D Investment Scoreboard , 2016 .

[48]  R. Pielke,et al.  The neglected heart of science policy: reconciling supply of and demand for science , 2007 .

[49]  A. Stirling,et al.  The value of structural diversity: assessing diversity for a sustainable research base , 2015 .

[50]  C. Begley,et al.  Drug development: Raise standards for preclinical cancer research , 2012, Nature.

[51]  Sarah Huggett,et al.  Gender in the Global Research Landscape raw data , 2017 .

[52]  M. Hopkin.  RNAi scoops medical Nobel , 2006, Nature.

[53]  Published Online.  Biomedical research: increasing value, reducing waste , 2014 .

[54]  Joe Devine,et al.  Annual Report and Financial Statements , 1987, Papers and Proceedings of the Royal Society of Tasmania.

[55]  Mark A. Burgman,et al.  Trusting Judgements: How to Get the Best out of Experts , 2015 .

[56]  Paul Bivand.  Labour market statistics , 2019, Data in Society.

[57]  James Wilsdon,et al.  Powerhouse of Science? Prospects and Pitfalls of Place-Based Science and Innovation Policies in Northern England , 2018 .

[58]  Paul Nightingale,et al.  The myth of the biotech revolution: An assessment of technological, clinical and organisational change , 2007 .

[59]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[60]  David Moher,et al.  Assessing scientists for hiring, promotion, and tenure , 2018, PLoS biology.

[61]  Life expectancy at birth and at age 65 by local areas in the United Kingdom, 2004–06 to 2008–10 , 2011 .

[62]  M. Baker.  1,500 scientists lift the lid on reproducibility , 2016, Nature.

[63]  Industrial Strategy.  Industrial strategy: building a Britain fit for the future , 2017 .

[64]  S. Jasanoff,et al.  Dreamscapes of Modernity: Sociotechnical Imaginaries and the Fabrication of Power , 2015 .

[65]  Stevienna de Saille,et al.  Review of diversity and inclusion literature and an evaluation of methodologies and metrics relating to health research , 2017 .

[66]  B. Flyvbjerg.  What you Should Know about Megaprojects and Why: An Overview , 2014, 1409.0003.

[67]  P. McCann.  The UK Regional-National Economic Problem: Geography, globalisation and governance , 2016 .

[68]  Michael Kitson,et al.  Pathways to impact and the strategic role of universities: new evidence on the breadth and depth of university knowledge exchange in the UK and the factors constraining its development , 2012 .

[69]  Stephen Hanney,et al.  Medical Research: What's It Worth? Estimating the Economic Benefits from Medical Research in the UK , 2009 .

[70]  Paul Nurse,et al.  Ensuring a successful UK research endeavour : a review of the UK research councils , 2015 .

[71]  Sheila Jasanoff,et al.  Crispr democracy: Gene editing and the need for inclusive deliberation , 2015 .

[72]  Matthew L. Thomas,et al.  Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015 , 2017, The Lancet.

[73]  Samuel A. Moore,et al.  Erratum: “Excellence R Us”: university research and the fetishisation of excellence , 2017, Palgrave Communications.

[74]  Harold Varmus,et al.  Rescuing US biomedical research from its systemic flaws , 2014, Proceedings of the National Academy of Sciences.

[75]  Lu Hong,et al.  Groups of diverse problem solvers can outperform groups of high-ability problem solvers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[76]  G. Mulgan.  Big Mind: How Collective Intelligence Can Change Our World , 2017 .

[77]  P. Glasziou,et al.  Avoidable waste in the production and reporting of research evidence , 2009, The Lancet.

[78]  J. Kay.  Obliquity: Why Our Goals Are Best Achieved Indirectly , 2010 .

[79]  J. O'Neill,et al.  Tackling drug-resistant infections globally: final report and recommendations , 2016 .

[80]  Sheila Jasanoff,et al.  A global observatory for gene editing , 2018, Nature.

[81]  F. Prinz,et al.  Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.